Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news code_execution wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

Resolution hinges on whether US annual measles cases average ≥5,000 across 2025-2028, versus ~1,600-2,400 confirmed in 2025 (a post-1992 record). That requires a large escalation, so I need the 2025 final CDC count, 2026 YTD trajectory, MMR coverage/elimination-status trends, and the market's own price as anchor.

# Current state The market resolves YES if the 2025–2028 average annual US measles case count is ≥5,000. 2025 finished at ~2,289–2,300 confirmed cases (highest since 1991); 2026 YTD (as of late July) already exceeds 2025's full-year total at ~2,318 and rising, putting 2026 on a similar or higher full-year trajectory. Kalshi currently prices this outcome at 29% YES, having drifted down slightly over the past 7–30 days. # Timeline of key events - 2025-01 to 2025-08: Southwest US measles outbreak (Texas/Gaines County-centered), spreads to NM, OK, KS; 3 deaths, ~99+ hospitalized; declared over 2025-08-18 (confirmed, Wikipedia). - 2025 (full year): CDC confirms 2,289 (revised from 2,144/2,255 in various reports) measles cases across 44 states, ~50 outbreaks — highest since 1991 (confirmed, CDC/AAP News). - 2025-11: PAHO announces the Americas region (including US and Canada) has lost measles elimination status due to endemic transmission >12 months, largely driven by Canada (5,463 cases in 2025) (confirmed, PAHO/CIDRAP). - 2026-06-18/20: Measles spreads to 41 states; 2,104 cases confirmed; 3 deaths total; commentary that US nearing loss of elimination status (confirmed CDC data, reported analysis). - 2026-07-06: CDC update to 2,170 cases, "nearing record levels with months remaining" (confirmed). - 2026-07-23/24: CDC confirms 2,318 cases for 2026, surpassing full-year 2025 total; largest count in 35 years; 93% outbreak-associated; top states SC (670), UT (518), TX (182) (confirmed, CDC/NBC/ABC). - 2026-11 (scheduled): PAHO Regional Verification Commission to formally review US (and Mexico) elimination status (scheduled/reported). # Event Kalshi market KXAVGMEASLESDJT-29-5000: will the 2025–2028 average annual US measles case count be ≥5,000? # Outcomes to forecast - Yes (average ≥5,000) - No (average <5,000) # Kalshi market anchor Current YES price: **29%** (down from 30%/36% highs over 30 days; 7-day change -1pt, 30-day change -1pt). Average daily volume ~154 contracts over 54 data points — thin but persistent trading. Price range over period: 28%-36%. # Sub-question answers 1. **2025 final CDC count vs. prior years** — 2025 finished at ~2,289 confirmed cases (some sources cite 2,144 or 2,255 pre-revision), the highest since 1991, far above 2024 (285) and above 2019 (1,274). [claude_news/CDC/Wikipedia] 2. **2026 YTD pace** — As of July 23-24, 2026, 2,318 confirmed cases already surpass all of 2025, with 93% outbreak-associated across 44 jurisdictions; implies a full-year 2026 total likely in the 2,500-4,000+ range if pace continues, but no direct extrapolation given in research. [claude_news, CDC] 3. **Required 2026-28 average for 4-yr mean ≥5,000** — Given 2025≈2,300, 2026-2028 would need to average ~5,900-6,100/year (sum ~17,700-18,300), 2-3x the 2019 US record (1,274) and roughly 2.5x current 2025/2026 levels, sustained for three straight years. [code_execution] 4. **Vaccination deterioration / elimination status** — Kindergarten MMR coverage fell from 95.2% (2019-20) to 92.5% (2024-25), ~286,000 at-risk kindergartners; ~93% of cases are unvaccinated/unknown status. The Americas region (incl. US) formally lost elimination status in Nov 2025; US-specific PAHO review scheduled Nov 2026, with experts arguing the US has "functionally" already lost it. [claude_news, PAHO, CIDRAP] 5. **HHS/ACIP policy changes** — Research raw output did not surface specific RFK Jr./HHS policy changes (ACIP composition, schedule changes, funding cuts) with clear causal case-count impact; this remains a gap. 6. **Lower-threshold pricing/probability distribution** — No Polymarket matches found. Kalshi-only data; no explicit prices for 1,000/2,000/3,000 thresholds retrieved, but Monte Carlo modeling estimates P(≥1,000)≈100%, P(≥2,000)≈93%, P(≥3,000)≈48%, P(≥5,000)≈25%, showing mass concentrated in 2,000-4,000 range. [code_execution] # Key facts (high-confidence, factual) 1. [CDC/AAP] 2025 US measles cases: ~2,289 confirmed, highest since 1991. 2. [CDC/NBC/ABC, 2026-07-24] 2026 YTD: 2,318 cases, surpassing 2025 total, 35-year high. 3. [PAHO, 2025-11] Americas region lost measles elimination status; US review set for Nov 2026. 4. [claude_news] Kindergarten MMR coverage down to 92.5% (2024-25) from 95.2% (2019-20). 5. [Wikipedia] 2025 Southwest outbreak (TX-centered) caused 3 deaths, declared over Aug 2025. 6. [code_execution] Required 2026-28 average of ~5,900-6,100/yr to hit 5,000 4-yr average is 2-3x the pre-2025 US modern record. # Cross-market signals - Kalshi related: same market only (KXAVGMEASLESDJT series); no lower-threshold sibling markets surfaced in tool output. - Polymarket: no matching markets found (0/100 scanned). - Sportsbook implied: N/A (not applicable to health/epidemiology market). # Analyst opinions and speculation - CIDRAP op-ed: US has "functionally lost" elimination status even ahead of formal Nov 2026 review. - WSWS/commentary pieces frame 2026 case counts as met with "official silence," implying political/policy undercoverage — unverified framing, not a hard fact. - Modeling (code_execution) frames ≥5,000 threshold as requiring "epidemic-scale" recurrence (10,000-15,000+ in at least one-two future years), not mere continuation of current elevated baseline. # Directional lean per outcome - **Yes (≥5,000 average)**: Supported by worsening vaccination trends, loss of regional elimination status, expanding multi-state outbreaks (SC, UT, TX), 2026 already exceeding 2025. Opposed by the sheer scale required: 2026-28 must average ~6,000/year, 2-3x any modern US year (2019 record 1,274), and both 2025/2026 are only tracking ~2,300. - **No (<5,000 average)**: Supported by consistent ~2,200-2,400/year pace across two consecutive years, no single year yet near 5,000 let alone 10,000+; Monte Carlo modeling puts P(≥5,000) at only ~25%. Opposed by tail risk of accelerating under-vaccination and possible large-scale outbreak(s) in 2027-2028. # Gaps / unknowns - No confirmed full-year 2026 final total (only YTD through ~July). - No specifics found on HHS/ACIP policy shifts under RFK Jr. and their case-count impact. - No Kalshi/Polymarket pricing for adjacent lower thresholds (1,000/2,000/3,000) to triangulate market-implied distribution shape. - 2027-2028 trends entirely unknown/unmodeled beyond simulation. # Calibration anchors - Kalshi current YES price: **29%** (primary anchor). - Independent Monte Carlo estimate: P(4-yr avg ≥5,000) ≈ 23-25%, roughly consistent with Kalshi's 29%, suggesting market is reasonably calibrated, perhaps modestly above model-implied fair value. - Historical precedent: pre-2025 modern-era single-year US max was 1,274 (2019); 2025/2026 both ~2,300 — already unprecedented, but still far below the ~6,000/yr needed for three consecutive years to hit the 5,000 threshold.

1. Both forecasters converge tightly around 23-27%, essentially deferring to the Monte Carlo/Kalshi anchors without independently stress-testing the tail-risk pathway (10,000-15,000+ case year) that the brief explicitly flags as "the main YES pathway" — neither quantifies how plausible such an epidemic-scale event actually is given accelerating MMR decline (95.2%→92.5% in five years) and formal loss of elimination status, which could compound nonlinearly (herd immunity collapse is not linear with coverage decline). 2. Neither forecast addresses the timing asymmetry: even a single catastrophic outbreak year (e.g., 2027 or 2028) could push the 4-year average across 5,000 even if the other years stay ~2,300-4,000 — this makes the question less about "sustained 6,000/yr" and more about "does at least one Disneyland-2015-style or Samoa-2019-style explosive outbreak occur in a large under-vaccinated pocket," a scenario that deserves more explicit probability decomposition rather than treating the requirement as a smooth average. 3. The brief notes the 2026 full-year projection is genuinely uncertain ("2,500-4,000+ range if pace continues, but no direct extrapolation given"), yet both forecasts casually cite "3,000-4,000" as if settled — if 2026 comes in at the higher end (or accelerates further into fall/winter respiratory season), the required 2027-28 average drops materially, which neither forecaster explicitly re-computes as a conditional sensitivity. 4. Sub-question 5 (HHS/ACIP policy changes under RFK Jr.) is flagged as a research gap with no findings, yet this is potentially the single largest wildcard for future-year case counts (vaccine policy, funding cuts, school exemption rules) — both forecasters mention "structural deterioration" generically but neither flags this specific unresolved gap as a reason for wider uncertainty bands or a fatter tail. 5. Both forecasters anchor to the Monte Carlo estimate (23-25%) as if it were an independent validation of Kalshi's price, but the model's inputs/assumptions aren't detailed in the brief — this risks circularity if the Monte Carlo was itself calibrated loosely to similar base rates rather than an independent structural epidemic model with vaccination-network dynamics. 6. Neither forecast discusses the PAHO Nov 2026 US-specific elimination review as a potential catalyst/inflection point — formal declaration of US loss of elimination status could itself change reporting practices, outbreak response funding, or public attention in ways that shift the 2027-28 trajectory, an event-driven consideration entirely absent from both rationales.

26% (medium confidence)

Yes: 26% No: 74%

With 2025 at ~2,289 and 2026 tracking toward roughly 3,000-4,000, the 2027-2028 years would need to average ~6,500-7,500 cases (or one explosive 12,000+ year) to lift the four-year mean to 5,000 — far beyond anything the US has recorded in the modern era. Both base forecasts correctly identify this scale barrier, but the critique is right that the YES pathway is really a single-epidemic-year tail event, not a smooth sustained escalation, and that fat-tail drivers (kindergarten MMR at 92.5% with nonlinear herd-immunity collapse, formal loss of elimination status, unmodeled HHS/ACIP policy shifts) justify not shading meaningfully below the market. I therefore weight slightly above the Monte Carlo estimate (23-25%) and just below the Kalshi anchor (29%), landing at 26%. The consistent ~2,300/year pace across two consecutive record years remains the dominant evidence pointing to NO.

Total pipeline time: 251.1s